[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100486225":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":64,"collaborators":67,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":10,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":10,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":10,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Indiana University","OTHER",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Surgical\u002FSurveillance",null,"TCS cured with surgical resection and surveillance (surgical\u002Fsurveillance, Arm 1)",[13,14,15],"Diagnostic Test: Lipid profile","Diagnostic Test: Coronary artery assessment","Diagnostic Test: Hormone levels for hypogonadism",{"label":17,"type":10,"description":18,"interventionNames":19},"Cisplatin-based chemotherapy (CBCT)","TCS treat with one or more lines of cisplatin-based chemotherapy",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Cisplatin-based chemotherapy and Bone Marrow Transplant (CBCT\u002FBMT)","TCS treat with one or more lines of cisplatin-based chemotherapy, and who have undergone bone marrow transplant",[13,14,15],[25,30,34],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"DIAGNOSTIC_TEST","Lipid profile","Advanced lipid profile",[17,21,9],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"Coronary artery assessment","Coronary artery assessment via CT scans",[17,21,9],{"type":26,"name":35,"description":35,"armGroupLabels":36,"otherNames":10},"Hormone levels for hypogonadism",[17,21,9],[38],{"name":39,"affiliation":5,"role":40},"Noah Richardson, MD","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},"Elizabeth Rowe","CONTACT","317-278-1185","rowee@iu.edu",[48],{"facility":5,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Indianapolis","Indiana","46202","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-86.15804,39.76838,{"lat":59,"lon":58},[62],{"name":43,"role":44,"phone":63,"phoneExt":10,"email":46},"(317) 278-1185",{"type":40,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Noah Richardson","Assistant Professor of Clinical Medicine",[68,71],{"name":69,"class":70},"National Institutes of Health (NIH)","NIH",{"name":72,"class":73},"JDS Foundation Testis Cancer Clinical Trials Support Fund","UNKNOWN","100486225","late-subclinical-cardiovascular-disease-in-testicular-cancer-survivors-100486225",false,"NCT05611307","Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors","Detection of Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors Exposed to Cisplatin-based Chemotherapy and Bone Marrow Transplant","Inclusion Criteria\n\n* Patients \\>18 years of age\n* Patients will be recruited only if cancer-free at clinical evaluation time.\n* For the cases a confirmed TC diagnosis who received one or more cycles of CBCT-based chemotherapies (CBCT group, Arm 2)\n* For the cases with a confirmed TC diagnosis who received one or more cycles of CBCT-based chemotherapies and underwent BMT for relapsed refractory disease (CBCT \\& BMT group, Arm 3).\n* For the comparison cohort, biopsy-proven TC patients who had surgery for or surveillance of their testicular cancer and never received CBCTCBCT or BMT (surgical\u002Fsurveillance, Arm 1)\n\nExclusion Criteria\n\n* Prior known myocardial infarction (MI), atherosclerotic cardiovascular disease (ASCVD)\n* Significant renal disease (GFR\\\u003C40)\n* Allergy to iodinated contrast\n* Antecedent chemotherapy for another primary cancer.","MALE","18 Years","99 Years",{"count":85,"type":86},150,"ESTIMATED","OBSERVATIONAL","Late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin-based chemotherapy and bone marrow transplant",[90,91,92,93,94,95,96,97],"Testicular Cancer","Survivorship","ASCVD","Coronary Artery Disease","Lipid Disorder","Hypogonadism, Male","Cisplatin Adverse Reaction","Bone Marrow Transplant Complications","2026-07-23",{"date":100,"type":101},"2026-07-27","ACTUAL",{"date":103,"type":101},"2022-10-11",{"date":105,"type":86},"2027-08",{"name":5,"class":6},1]